Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | PRF1 | P14222 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138175 | 0.86 | MAPK1 (0.34) | MAPK1PARP10PARP1P2RX7CD274 | |
| SCHEMBL20138313 | 0.85 | MAPK1 (0.41) | MAPK1PARP10PARP1CD274PARP11 | |
| SCHEMBL20138280 | 0.85 | MAPK1 (0.41) | MAPK1PARP10PARP1CD274PARP11 | |
| SCHEMBL20138264 | 0.81 | NR1H2 (0.37) | MTOR | |
| SCHEMBL20138227 | 0.80 | CD274 (0.38) | MAPK1PARP10PARP1CD274PARP11 | |
| SCHEMBL20138206 | 0.78 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL20138307 | 0.74 | MAPK1 (0.42) | MAPK1PARP10PARP1CD274PARP11 | |
| SCHEMBL20138136 | 0.70 | TSHR (0.41) | P2RX7 | |
| SCHEMBL20138260 | 0.69 | MAPK1 (0.41) | MAPK1PARP10PARP1CD274MTOR | |
| SCHEMBL20138130 | 0.69 | MAPK1 (0.42) | MAPK1PARP10PARP1CD274MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | MAPK1 1235/4885PARP10 1687/4885PARP1 1553/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | MAPK1 1268/4885PARP10 3857/4885PARP1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.